

## EXPRESS MAIL CERTIFICATE

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Typed or Printed Name	David Glisson	Express Mail No.	EL 284 101 823 US
Signature	<i>David Glisson</i>	Date	March 20, 2000

Form PTO-1390  
(REV 10-94)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

SHIM-004

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

09/508997

U.S. APPLICATION NO.

To Be Assigned

INTERNATIONAL APPLICATION NO.  
PCT/JP98/04269

INTERNATIONAL FILING DATE  
September 22, 1998

PRIORITY DATE CLAIMED  
September 22, 1997

TITLE OF INVENTION

"MEGSIN PROTEIN"

APPLICANT(S) FOR DO/EO/US

Toshio Mivata

I, the undersigned, do hereby submit to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2)):
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau. (**However, a courtesy copy is attached hereto.**)
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (37 U.S.C. 371(c)(3)):
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (**UNSIGNED**)
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
  - Return Postcard
  - Sequence Listing (Certification Regarding Sequence Listing; Paper Copy of Sequence Listing; Diskette of Sequence Listing)

U.S. APPLICATION NO (If known, see 37 CFR 1.50) To Be Assigned <b>09/508997</b>		INTERNATIONAL APPLICATION NO PCT/JP98/04269		ATTORNEY'S DOCKET NUMBER SHIM-004	
17. <input checked="" type="checkbox"/> The following fees are submitted: <b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b>  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and international search report not prepared by the EPO or JPO ..... \$970.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search report prepared by the EPO or JPO ..... \$840.00  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$690.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$ 96.00					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$ 840.00	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than _____ 20 _____ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	21 - 20 =	1	X \$18.00	\$ 18.00	
Independent Claims	2 - 3 =	0	X \$78.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$ 260.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1,118.00	
Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28)				\$	
<b>SUBTOTAL =</b>				\$ 1,118.00	
Processing Fee of <b>\$130.00</b> for furnishing the English translation later than _____ 20 _____ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
<b>TOTAL NATIONAL FEE =</b>				\$ 1,118.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				\$	
<b>TOTAL FEES ENCLOSED =</b>				\$ 1,118.00	
				Amount to be: refunded	\$0.00
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1,118.00</u> to cover the above fees is included. b. _____ Please charge my Deposit Account No. 50-0815 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0815.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO Karl Bozicevic BOZICEVIC, FIELD & FRANCIS LLP 285 Hamilton Avenue, Suite 200 Palo Alto, California 94301 (650) 327-3400 Telephone (650) 327-3231 Facsimile			<div style="font-size: 2em; margin-bottom: 10px;">3/20/00</div> <div style="text-align: right;">             SIGNATURE            Karl Bozicevic            NAME            28,807            REGISTRATION NUMBER         </div>		

7/ppts

09/508997

430 Rec'd PCT/PTO 20 MAR 2000

- 1 -

## SPECIFICATION

### MEGSIN PROTEIN

#### 5 Technical Field

The present invention belongs to the field of genetic engineering and specifically relates to a gene isolated from renal cells.

#### 10 Background Art

Sixty trillion various cells *in vivo* essentially comprise identical genomic DNA. For the normal physiological functions, the expression of these genes is strictly controlled by signals received by cell lines and cells. Therefore, elucidation of  
15 genes expressed specifically in each cell type is very important.

A mesangial cell plays a pivotal role in maintaining the structure and function of a glomerulus and is a target of disorders for each type of nephritis. For example, proliferation of mesangial cells and accumulation of extracellular mesangial  
20 matrix are thought to be the first step developing glomerulosclerosis in a patient suffering from various glomerular diseases such as chronic nephritis and diabetic nephritis. Therefore, identification of genes expressed specifically in mesangial cells and elucidation of its function  
25 are helpful for understanding biological characteristics of mesangial cells and the causes of diseases relating to mesangial cells, and in turn, treating or diagnosing diseases relating to mesangial cells.

Thyl antigen is known as a marker for mesangial cells in  
30 rats. However, this gene is not specific to mesangial cells and is not expressed in human mesangial cells (Miyata T. et al., Immunology, 1989, 67: 531-533; and Miyata T. et al., Immunology, 1990, 69: 391-395). Mesangial cells are known to express  $\alpha$  smooth muscle actin when activated, but this gene is also not  
35 specific to mesangial cells. Any genes expressed specifically in mesangial cells have not been reported.

09/508997 20000320

Disclosure of the Invention

An objective of the present invention is to isolate a gene expressed specifically in mesangial cells.

5       The current inventors isolated mRNA from *in vitro* cultures of human mesangial cells to construct a cDNA library of 3' side. Sequences of numerous clones were randomly determined from the cDNA library and compared with the known nucleotide sequences of cDNA clones of 3' side obtained from various organs and cells  
10       to determine the clones expressed specifically in mesangial cells. One clone which appeared the most frequently in the mesangial cells was selected, and its full length cDNA was isolated (the expression product was named as MEGSIN) by 5' RACE method to determine the whole nucleotide sequence and express the said cDNA  
15       in *E. coli* (SEQ ID NO: 1 and SEQ ID NO: 2 show the nucleotide sequence of human MEGSIN cDNA and the deduced amino acid sequence, respectively). The homology search in amino acid sequences with SwissProt data base revealed that MEGSIN belongs to SERPIN super family (R. Carrell et al., Trends Biochem Sci. 10, 20, 1985; R.  
20       Carrell et al., Cold Spring Harbor Symp. Quant. Biol. 52, 527, 1987; E. K. O. Kruithof et al., Blood 86, 4007, 1995, J. Potempa et al., J. Biol. Chem. 269, 15957, 1994; and E. Remold-O'Donnell FEBS Let. 315, 105, 1993). The topography detected by Northern blotting confirmed that the expression of MEGSIN was weak in human  
25       fibroblasts, smooth muscle cells, endothelial cells, and keratinocytes, and was specifically in mesangial cells. The comparison of MEGSIN expression level in renal tissues from the IgA nephropathy patients and the normal people revealed that the expression level of MEGSIN in the IgA nephropathy patients was  
30       significantly larger. Anti-MEGSIN polyclonal antibody and monoclonal antibody were prepared. In addition, the inventors confirmed the structures of mouse and rat MEGSIN homologues. The nucleotide sequences of cDNA of mouse MEGSIN and rat MEGSIN are shown in SEQ ID NO: 3 and SEQ ID NO: 5, respectively, and the  
35       deduced amino acid sequences for these are shown in SEQ ID NO: 4 and SEQ ID NO: 6, respectively.

002290 2666560

The present invention specifically relates to the followings.

(1) A protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or a protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 in which one or more amino acids are replaced, deleted, added, and/or inserted, and functionally equivalent to the protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6

(2) The protein of (1), comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6.

(3) A DNA encoding the protein of (1).

(4) The DNA of (3), comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 5.

(5) A DNA hybridizing with a DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 5 under the stringent condition, and encoding the protein of (1) or the protein functionally equivalent thereto.

(6) A vector comprising the DNA of any one of (3), (4), and (5).

(7) A transformed cell expressibly comprising the DNA of any one of (3), (4), and (5).

(8) A method for producing the protein of (1), the method comprising culturing the transformed cell of (7) and collecting an expression product of the DNA of any one of (3), (4), and (5).

(9) An antibody binding to the protein of (1).

(10) The antibody of (9), which recognizes an epitope of a protein comprising an amino acid sequence selected from amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.

(11) The antibody of (10), wherein the antibody is a monoclonal antibody.

(12) An immunoassay method for measuring the protein of (2) or its fragment, the method comprising immunologically binding the antibody of any one of (10) and (11), to the protein of (2) or its fragment.

(13) A reagent for an immunoassay for the protein of (2) or its fragment, comprising the antibody of any one of (10) and (11).

(14) A method for detecting mesangial proliferative nephropathy, the method comprising measuring the protein of (2) or its fragment  
5 contained in biological samples and comparing the measured amount with that obtained from normal samples.

(15) A transgenic nonhuman vertebrate, wherein the expression level of the gene encoding MEGSIN is modified.

(16) The transgenic nonhuman vertebrate of (15), wherein the  
10 nonhuman vertebrate is a mouse.

(17) The transgenic nonhuman vertebrate of (16), which is a knockout mouse wherein expression of the gene encoding MEGSIN is inhibited.

A full length cDNA library often comprises the sequences  
15 with different 5' ends in the same transcript due to the partial degradation of mRNA and the incomplete synthesis of the first strand. In addition, the nucleotide sequence of the 3' end is difficult to determine by the chain termination method using general primers due to the gap of primer extension on poly (A).  
20 A random prime cDNA library used for constructing EST data base is useful for finding a novel gene, however, can not be used for obtaining typical sequences of genes because it is not clear whether two partial sequences form different parts of a gene, or different transcripts. Therefore the present inventors used  
25 3'-directed cDNA library. Through this method, unstable cloning efficiency reflecting the size of cDNA can be avoided. The sequence at the 3' region is typical, and the sequence data of about 200 to 300 bp are large enough for investigating the characteristics of a gene.

30 The DNA encoding human MEGSIN of the present invention can be obtained by preparing mRNA from mesangial cells and converting them to the double stranded cDNA by the known methods. mRNA can be prepared by, for example, the guanidine isothiocyanate-cesium chloride method (Chirwin, et al., Biochemistry 18, 5294, 1979),  
35 and the treatment with a surfactant and phenol in the presence of deoxyribonuclease (Berger & Birkenmeier, Biochemistry 18,

5143, 1979), etc. Poly (A)<sup>+</sup> RNA can be prepared from total RNA by, for example, the affinity chromatography using such a carrier bound to oligo (dT) as Sepharose, cellulose, latex particles, etc. DNA (cDNA) complementary to the mRNA can be obtained by  
5 treating RNA obtained in the above manner as a template with reverse transcriptase using oligo (dT) complementary to poly (A) strand at 3' end a random primer, or a synthetic oligonucleotide corresponding to a part of amino acid sequence of MEGSIN as primers. Hybrid mRNA-cDNA strand thus obtained can be converted to a double  
10 stranded cDNA by replacing the mRNA with a DNA strand by, for example, treating with *E. coli* RNase H, *E. coli* DNA polymerase I, and *E. coli* DNA ligase.

The DNA can be cloned by RT-PCR method using poly (A)<sup>+</sup> RNA from mesangial cells as a template, primers synthesized based  
15 on the human MEGSIN gene nucleotide sequence. Alternatively, without using PCR, the target cDNA can be obtained by directly screening a cDNA library with a probe synthesized based on human MEGSIN gene nucleotide sequence. The gene of the present invention can be selected by confirming the nucleotide sequence  
20 of the gene among the genes obtained by these methods. For mouse and rat MEGSIN, cDNA can be obtained by the same method.

Mouse and rat MEGSIN cDNA can be isolated as follows. mRNA is extracted from tissues of a mouse or rat, or cultured mesangial cells using three kinds of probes based on from the above human  
25 MEGSIN cDNA, which are a relatively highly conserved region (197-380 A. A.), a relatively less conserved region (1-196 A. A.), compared with genes of other SERPIN super family protein, and full length cDNA of MEGSIN open reading frame (1-380 A. A.) to construct a cDNA library. Colony hybridization is then  
30 performed using the above library or a commercially available cDNA library (Funakoshi) . Alternatively, as similar to the probe preparation above, primers can be designed based on a relatively highly conserved region (197-380 A. A.) and a relatively less conserved region (1-196 A. A.), and RT-PCR can  
35 be conducted using mRNA extracted from tissues of a mouse or rat, or cultured mesangial cells for cloning to obtain mouse or rat

MEGSIN cDNA. The genome can be obtained by conducting plaque hybridization method using a commercially available library (Funakoshi) in the same manner as in the case of obtaining the human genome.

5 Human MEGSIN genome can be obtained by plaque hybridization method (refer to Shin Saibou Kougaku Jikken (New Cell Biotechnology Experiment) Protocols, Shujun-sha, pp79-92) using the whole region of known MEGSIN cDNA open reading frame (1143 bp) or using as a probe each exon-intron part obtained by  
10 amplifying human genomic DNA through PCR method using a part of cDNA as primers as a probe, and a genomic library obtained by inserting DNA partially digested genomic DNA prepared from human B lymphoblast with *Sau3* into phage vector EMBL3, or by inserting a human X chromosome library into phage vector Charon 35 (refer  
15 to Blood, vol. 83, No. 11, 1994, pp3126-3131). A sequence of 5' UT region of the control region sequence can be determined by 5' RACE method (5'-Full RACE Core Set, following Takara's protocol) using human cultured mesangial cell-derived mRNA or human renal mRNA (purchased from Clontech) as a template.

20 The gene of the present invention can also be produced by following the standard methods using chemical synthesis of nucleic acids, such as phosphoramidite method (Mattencci, M. D. & Caruthers, M. H. J. Am. Chem. Soc. 103, 3185, 1981), phosphite triester method (Hunkapiller, M. et al., Nature 310, 105, 1984).

25 An eukaryotic gene often shows polymorphism, like human interferon gene, and one or more amino acids may be replaced by this polymorphism with maintaining activities of a protein. In general, activities of proteins can be often maintained even if one or more amino acids are modified. Therefore, any gene  
30 encoding a protein obtained by using the artificially modified gene encoding an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 is included in this invention as long as the protein possesses the function typical to the gene of the present invention. The present invention includes any protein in which  
35 an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 is artificially modified as long as it has characteristics



of the proteins of the present invention.

The proteins of the present invention comprise an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or the amino acid sequences in which one or more amino acids are replaced, deleted, added, and/or inserted, and belong to the SERPIN super family. The SERPIN super family means proteins whose amino acid sequence is at least 20% identical to primary serine protease inhibitors in blood, such as antithrombin III, heparin cofactor II,  $\alpha$ 1-antitrypsin,  $\alpha$ 1-antichymotrypsin, protein C inhibitor,  $\alpha$ 2-plasmin inhibitor, C1 inhibitor, etc., and which does not necessarily show serine protease inhibitory activity (refer to R. Carrell et al., Trends Biochem. Sci. 10, 20, 1985; R. Carrell et al., Cold Spring Harbor Symp. Quant. Biol. 52, 527, 1987; E. K. O. Kruithof et al., Blood 86, 4007, 1995, J. Potempa et al., J. Biol. Chem. 269, 15957, 1994; and E. Remold-O'Donnell. FEBS Let. 315, 105, 1993).

The proteins of the present invention include a "protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or the amino acid sequence in which one or more amino acids are replaced, deleted, or added, and/or inserted, and expressed weakly in human fibroblasts, smooth muscle cells, endothelial cells, keratinocytes, and expressed in mesangial cells." Alternatively, the proteins of the invention include a "protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or the amino acid sequence in which one or more amino acids in these amino acid sequences are replaced, deleted, added, and/or inserted, and strongly expressed especially in mammalian mesangial cells." Moreover, the proteins of the present invention include a "protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or the amino acid sequence in which one or more amino acids are replaced, deleted, added, and/or inserted, and comprising serine protease inhibitory activity," etc. These analogues are all encompassed by MEGSIN of the present invention. Therefore, not only human, rat, and mouse MEGSIN which structure is specifically described, but also the homologues of other

species structurally or functionally equivalent to these are included in the current invention.

The DNA of the present invention includes DNAs encoding these proteins. The DNAs encoding these proteins can be cDNA,  
5 genomic DNA, or synthetic DNA.

The codons for desired amino acids themselves are well-known, can be optionally selected, and can be determined by following the standard method by, for example, considering the frequency of use of codons in hosts to be used (Grantham,  
10 R. et al. Nucleic Acids Res. 9, r43, 1981). Therefore, the present invention includes DNAs modified by degeneration of codons. These partial modifications of codons of nucleic acid sequence can be performed by site specific mutagenesis using primers composed of synthetic oligonucleotide encoding desired  
15 modification following standard methods (Mark, D. F. et al. Proc. Natl. Acad. Sci. U. S. A. 81, 5662, 1984).

Any DNA hybridizing with DNA containing the nucleotide sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5, and encoding a protein that typically functions as MEGSIN of the present  
20 invention, can be included in the DNA of the present invention. A sequence capable of hybridizing with the above sequences under the stringent condition is thought to have the activities similar to a protein encoded by the above sequences.

The nucleotide sequences of DNAs of the present invention,  
25 including mutants, can be used for various purposes based on known techniques.

Other prokaryotic or eukaryotic hosts can be transformed by inserting the gene encoding MEGSIN cloned as described above into an appropriate vector. Moreover, the gene can be expressed  
30 in each host cell by introducing an appropriate promoter and sequences relating to the phenotypic expression into the vector. As an expression vector, for example, pET-3 (Studier & Moffatt, J. Mol. Biol. 189, 113, 1986), etc. for *E. coli*, pEF-BOS (Nucleic Acids Research 18, 5322, 1990) and pSV2-gpt (Mulligan & Berg,  
35 Proc. Natl. Acad. Sci. U. S. A. 78, 2072, 1981), etc. for COS cells, and pVY1 (W089/03874), etc. for CHO cells can be used.

The target proteins can be expressed as a fusion protein derived from a fusion gene between a target gene and a gene encoding other polypeptide. Such fusion proteins can easily be purified and separated to isolate a desired protein .

5       *Escherichia coli* can be used as prokaryotic host cells in the expression system of the present invention. *Saccharomyces cerevisiae*, etc. can be used as host cells among eukaryotic organisms. Examples of mammalian host cells include COS cells, CHO cells, BHK cells, etc. The transformants of the current  
10      invention can be cultured under appropriately selected culturing condition suitable for host cells.

MEGSIN can be produced by culturing the transformants transformed with the gene encoding the target MEGSIN, and recovering it from the microbial cells or the culture supernatant.

15      It can be purified into a substantially pure protein. MEGSIN, a target protein of the present invention, can be separated and purified by the separation and purification methods commonly used for proteins, and the method is not particularly limited. MEGSIN can be separated and purified by, for example, appropriately  
20      selecting and combining various chromatographies.

Besides the methods described above, the gene of the present invention, the recombinant vector comprising the gene, the transformants carrying the vector and the production of MEGSIN using gene manipulation can be manipulated by the standard  
25      method described in "Molecular Cloning - A Laboratory Manual" (Cold Spring Harbor Laboratory, N. Y.).

In addition, a probe for detecting a MEGSIN gene can be designed based on the nucleotide sequence of SEQ IN NO. 1, SEQ IN NO. 3, or SEQ IN NO. 5. Moreover, primers for amplifying DNA  
30      and RNA containing these nucleotide sequences can be designed. It is routine for a person skilled in the art to design probes and primers based on a given sequence . An oligonucleotide comprising a designed nucleotide sequence can be chemically synthesized. These oligonucleotides can be used for the  
35      hybridization assay of various formats, or for the synthetic reaction of nucleic acids, such as PCR, if appropriately labeled.

An oligonucleotide used as a probe or a primer has at least 15 bases, and preferably 25 to 50 bases.

A promoter region and an enhancer region of MEGSIN gene existing in genome can be obtained based on the cDNA nucleotide sequence of MEGSIN of the present invention. Specifically, these control regions can be obtained by the same method as described in unexamined published Japanese patent application (JP-A) No. Hei 6-181767, The Journal of Immunology, 1995, 155, 2477-2486, Proc. Natl. Acad. Sci. USA, 1995, 92, 3561-3565 etc. Herein, a promoter region means DNA region existing upstream of a transcription initiation site to control the expression of a gene, and an enhancer region means DNA region existing in an intron or 3' noncoding region to control expression of a gene.

Specifically, a promoter region can be obtained, for example, by the following method.

1) A promoter region of MEGSIN is cloned from a human genomic library using 5' end site of cDNA of MEGSIN as a probe.

2) MEGSIN gene is digested with restriction enzyme to obtain a DNA comprising the promoter region at the upstream region (2 to 5 kbp) containing a translation initiation codon of MEGSIN gene and determine the nucleotide sequence. The transcription initiation site (+1) is determined using poly (A)-RNA prepared from human mesangial cells as a template, by the primer elongation method using primer DNA selected from cDNA sequence at 5' end site of MEGSIN gene. A site possibly comprising the promoter activity is predicted by searching transcription factor binding sequence from the nucleotide sequence.

3) The DNA fragment excluding the coding region of MEGSIN gene from the DNA obtained in 2) is subcloned in a plasmid, and a chloramphenicol acetyl transferase (CAT) gene or a luciferase gene is ligated as a reporter gene at 2 to 5 kbp downstream of the DNA fragment to construct a reporter plasmid. Similarly, DNA fragments corresponding to various sites upstream of MEGSIN gene, in which 5' and 3' end sites are stepwise removed, are prepared by digestion with restriction enzymes or by PCR to include possible promoter regions. The CAT gene or the

luciferase gene is ligated as a reporter gene at downstream of these DNA fragments to construct a reporter plasmid.

- 4) A promoter region upstream of MEGSIN gene is obtained by measuring CAT or luciferase activity in animal cells transformed with the reporter plasmid prepared in 3).

A 3' noncoding region and an enhancer region having an enhancer activity in introns can be obtained by cloning genomic genes of human MEGSIN from a human genomic library using MEGSIN cDNA as a probe in the same manner as described above for the promoter.

Transcription factors controlling the expression of MEGSIN gene can be obtained by the known methods, for example, those described in "Shin Saibou Kougaku Jikken (New Cell Biology Experiment) Protocols, Shujun-sha," "Biomanual series 5 Tensha Inshi Kenkyu-hou (studies on transcription factors), Yodo-sha," "DNA & Cell Biology, 13, 731-742, 1994," such as affinity chromatography, South-western method, footprinting method, gel shift method, or one-hybrid method. Herein, a transcription factor means a factor controlling the transcription of MEGSIN gene, including a transcription initiation factor that induces the transcription initiation reaction and a transcription control factor that up- or downregulates transcription. Affinity chromatography can be performed by applying a nucleic extract to an affinity column in which promoter and enhancer regions obtained above are immobilized on Sepharose or latex beads, washing the column, eluting . the binding transcription factor using a DNA comprising the same sequence as that immobilized in the column, and recovering the transcription factor controlling the expression of MEGSIN gene.

In the case of South-western method, cDNA is inserted into an *E. coli* expression vector such as  $\lambda$ gt11, to synthesize a fusion protein with  $\beta$ -galactosidase. The fusion protein is adsorbed on a nitrocellulose membrane, and a phage which synthesizes the fusion protein showing binding activities is selected using radiolabeled DNA fragments of promoter and enhancer regions as probes to obtain the transcription factor controlling the

expression of MEGSIN gene.

The present invention also provides an antibody recognizing MEGSIN. The antibody of the present invention includes, for example, an antibody to the protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6. An antibody (for example, a polyclonal antibody, a monoclonal antibody) or an antiserum against MEGSIN or a partial peptide of MEGSIN of the present invention can be produced by a known method for producing an antibody and antiserum, using MEGSIN of the present invention, a partial peptide of MEGSIN of the present invention, or a fusion protein such as His-Tag-MEGSIN or MBP-MEGSIN of the present invention as an antigen. A monoclonal antibody can be produced by, for example, the following method.

The MEGSIN of the present invention or a partial peptide of MEGSIN of the present invention is administered alone or together with a carrier or diluent to a warm-blooded animal at the site capable of producing an antibody. To enhance the antibody productivity, the complete Freund's adjuvant or incomplete Freund's adjuvant can be administered together with the antigen. Immunization is performed every one to six weeks, a total of about 2 to 10 times, in general. Warm-blooded animals to be used are, for example, a monkey, rabbit, dog, guinea pig, mouse, rat, sheep, goat, and domestic fowl, and preferably a mouse and rat. Monoclonal antibody-producing cells can be prepared by selecting immunized warm-blooded animals, such as mice, in which an antibody titer is detected, obtaining spleen or lymph node from the animals 2 to 5 days after the final immunization, and fusing the antibody producing cells contained in these tissues with myeloma cells to obtain monoclonal antibody-producing hybridoma. The antibody titer in antiserum can be measured by reacting the labeled MEGSIN described below with antiserum, and measuring an activity of the label binding to the antibody. Cell fusion can be performed by a known method, for example, the method of Kohler and Milstein (Nature, 256, 495, 1975). Polyethylene glycol (PEG), Sendai virus, etc. can be used as a fusion enhancer, and PEG is preferable.

Examples of myeloma cells include X-63Ag8, NS-1, P3U1, SP2/0, AP-1, etc., and X-63Ag8 is preferably used. The ratio of the number of antibody-producing cells (splenic cells) to that of myeloma cells is 1:20 to 20:1. Cells can be fused efficiently by adding PEG (preferably PEG1000 to PEG6000) at the concentration of about 10 to 80 %, and incubating for 1 to 10 min at 20 to 40 °C, preferably at 30 to 37°C. Anti-MEGSIN antibody-producing hybridoma can be screened by various methods, for example, the method in which the hybridoma culture supernatant is added to a solid phase (for example, a microplate) on which MEGSIN antigen is adsorbed directly or with a carrier, and anti-immunoglobulin antibody labeled with a radioactive substance or an enzyme (When cells used for cell fusion are derived from a mouse, anti-mouse immunoglobulin antibody is used.) or protein A is added thereto, and anti-MEGSIN monoclonal antibody binding to the solid phase is detected, the method in which the hybridoma culture supernatant is added to a solid phase on which anti-immunoglobulin antibody or protein A is adsorbed, and MEGSIN labeled with a radioactive substance or an enzyme is added thereto, and anti-MEGSIN monoclonal antibody binding to the solid phase is detected.

Anti-MEGSIN monoclonal antibody can be selected and cloned by known methods or modified methods thereof using usually a culture medium for animal cells supplemented with HAT (hypoxanthine, aminopterin, and thymidine). Any medium for selection, cloning, and culturing can be used as long as hybridoma can grow therein,. For example, RPMI 1640 medium (Dainippon Pharmaceutical Co., Ltd.) containing 1 to 20%, preferably 10 to 20% of fetal bovine serum, GIT medium (Wako Pure Chemicals) containing 1 to 10% fetal bovine serum, or serum-free medium for hybridoma culturing (SFM-101, Nissui Pharmaceutical Co., Ltd.) can be used. Incubation temperature is generally 20 to 40°C, preferably about 37°C. Incubation time is generally 5 days to 3 weeks and preferably 1 to 2 weeks. Incubation is performed under the 5% carbon dioxide gas in general. The antibody titer of the hybridoma culture supernatant can be determined in the same manner as described above for the measurement of anti-MEGSIN antibody

titer in the antiserum. Cloning can be generally conducted by known methods, for example, semisolid agar method, or limiting dilution method. A cloned hybridoma is cultured preferably in a serum-free medium, thereby producing an optimal amount of an antibody in the supernatant. Preferably, a target monoclonal antibody can be obtained in ascites.

A monoclonal antibody of the present invention does not crossreact with other proteins other than MEGSIN by selecting those capable of recognizing epitopes specific to MEGSIN. In general, an epitope specific to a protein is composed of at least 7 or more continuous amino acid residues, preferably 10 to 20 amino acids in an amino acid sequence of the protein. Therefore, a monoclonal antibody recognizing an epitope composed of peptides having an amino acid sequence selected from the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, and composed of at least 7 continuous amino acid residues can be the monoclonal antibody specific to MEGSIN of the present invention. Conserved amino acid sequences among the amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6 can be selected to choose epitopes common in the MEGSIN family. If a region contains amino acid sequences specific to all sequences, a monoclonal antibody capable of recognizing different species can be selected.

An anti-MEGSIN monoclonal antibody can be separated and purified by the separation and purification method of immunoglobulin commonly used for the separation and purification of polyclonal antibodies. The known purification methods include, for example, salting out, alcohol precipitation, isoelectric point precipitation, electrophoresis, adsorption and desorption method by ion exchanger (for example, DEAE), ultra centrifugation, gel filtration, or specific purification method whereby antibody is exclusively collected by, for example, an antigen binding solid phase or active adsorbent, such as Protein A or Protein G, and the binding is dissociated to obtain the antibody.

Monoclonal antibodies and polyclonal antibodies recognizing MEGSIN of the present invention, obtained in such



a manner, can be used for the diagnosis and treatment for diseases relating to mesangial cells. Examples of a method for measuring MEGSIN with these antibodies include an sandwich assay comprising reacting MEGSIN with an antibody binding to an insoluble carrier and a labeled antibody and detecting MEGSIN in the sandwiched complex produced by the reaction, or a competition method comprising competitively reacting labeled human urine-derived MEGSIN and human urine-derived MEGSIN in a sample with an antibody to measure human urine-derived MEGSIN in a samples based on labeled antigen amount reacted with the antibody.

The measurement of human urine-derived MEGSIN by the sandwich method is conducted by the 2 step method in which an immobilized antibody is reacted with human urine-derived MEGSIN, unreacted materials are completely removed by washing, and a labeled antibody is added to form a complex of the immobilized antibody, the labeled human urine-derived MEGSIN antibody, or one step method in which the immobilized antibody, the labeled antibody, and human urine-derived MEGSIN are mixed at the same time.

Examples of an insoluble carrier used for the measurement include, for example, polystyrene, polyethylene, polypropylene, polyvinyl chloride, polyester, polyacrylate, nylon, polyacetal, synthetic resin such as fluoride resin, etc., polysaccharides such as cellulose, agarose, etc., glass, metals, etc. The form of an insoluble carrier can be varied and includes tray, spheroid, fiber, stick, board, container, cell, test tube, etc. The antibody-adsorbed carrier should be stored at a cool place in the presence of appropriate preservatives, such as sodium azide.

Antibodies can be immobilized by known chemical binding or physical adsorption methods. Chemical binding methods include, for example, a method using glutaraldehyde, the maleimide method using N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate, N-succinimidyl-2-maleimidoacetate, etc., and the carbodiimide method using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, etc. In addition, the maleimidobenzoyl-N-

hydroxysuccinimidoester method, the N-succimidyl-3-(2-pyridyldithio)propionate method, the bisdiazolated benzidine method, and dipalmityllysine method. Alternatively, the complex produced by reacting two different antibodies against a substance to be detected and an epitope is captured with the third antibody immobilized by the above method.

Any label useful for immunoassay can be used without being limited. Specifically, enzymes, fluorescent substances, luminescent substances, radioactive substances, metal chelates, etc. can be used. Preferable labeling enzymes are, for example, peroxidase, alkaline phosphatase,  $\beta$ -D-galactosidase, malate dehydrogenase, *Staphylococcus* nuclease, delta-5-steroid isomerase,  $\alpha$ -glycerol phosphate dehydrogenase, triosephosphate isomerase, horseradish peroxidase, asparaginase, glucose oxidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase, and acetylcholine esterase, etc.. Preferable fluorescent substances include, for example, fluorescein isothiocyanate, phycobiliprotein, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, and orthophthalaldehyde. Preferable luminescent substances include, for example, isoluminol, lucigenin, luminol, aromatic acridiniumester, imidazole, acridinium salt and its modified ester, luciferin, luciferase, and aequorine. Preferable radioactive substances include, for example,  $^{125}\text{I}$ ,  $^{127}\text{I}$ ,  $^{131}\text{I}$ ,  $^{14}\text{C}$ ,  $^3\text{H}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , etc.

The method for binding the above labels is known. Specifically, direct and indirect labeling can be used. The common direct labeling is the method in which an antibody or an antibody fragment is chemically covalent-bound with a label using a crosslinking agent. Crosslinking agents include N,N'-orthophenylenedimaleimide, 4-(N-maleimidomethyl)cyclohexanoate N-succinimide ester, 6-maleimidoheptanoate N-succinimide ester, 4,4'-dithiopyridine, and other known crosslinking agents. The crosslinking agent can be reacted with enzymes and antibodies by the known methods depending on the characteristics of the

crosslinking agent. An example of the indirect labeling method comprises binding an antibody to a low molecular weight hapten such as biotin, dinitrophenyl, pyridoxal, or fluorescamine, and indirectly labeling the antibody with the binding partner to the hapten. Avidin and streptoavidin can be used as a recognition ligand for biotin, whereas dinitrophenyl, pyridoxal, or fluorescamine are labeled with antibodies recognizing these haptens. Horseradish peroxidase can be used as a enzyme for labeling antibodies. This enzyme is useful because it can react with many substrates and be easily bound to antibodies by the periodate method. Occasionally, as an antibody, their fragments, for example, Fab', Fab, F(ab')<sub>2</sub> are used. Both polyclonal and monoclonal antibodies can be labeled with an enzyme by the same method. Enzyme-labeled antibodies obtained using the above crosslinking agent can be purified by the known methods such as affinity chromatography, etc. to serve in a more sensitive immunoassay system. Purified enzyme-labeled antibodies are stored with a preservative such as thimerosal and a stabilizer such as glycerol. Labeled antibodies can be lyophilized and stored in the cool and dark place for a long time.

When a label is an enzyme, its substrate and, if necessary, a coloring agent are used for measuring its activity. When peroxidase is used as an enzyme, H<sub>2</sub>O<sub>2</sub> is used as a substrate solution and 2,2'-azino-di-[3-ethylbenzothiazolinesulfonic acid] ammonium salt (ABTS), 5-aminosalicylic acid, orthophenylenediamine, 4-aminoantipyrine, or 3,3',5,5'-tetramethylbenzidine, etc. is used as a coloring agent. When alkaline phosphatase is used as an enzyme, orthonitrophenylphosphate, paranitrophenylphosphate, etc. can be used as substrates. When  $\beta$ -D-galactosidase is used as an enzyme, fluorescein-di-( $\beta$ -D-galactopyranoside), 4-methylumbelliferyl- $\beta$ -D-galactopyranoside, etc. can be used as substrates. The present invention also includes an immunoassay reagent for MEGSIN, comprising labeled or immobilized monoclonal or polyclonal antibodies, and further includes a kit comprising this reagent and an indicator for detection label and a control

sample, etc.

Any biological samples such as body fluid such as blood plasma, serum, blood, urine, tissue fluid, or cerebrospinal fluid etc. can be used as samples for measuring the MEGSIN of the present invention as long as they contain MEGSIN or its precursor or a fragment. Among these biological samples, especially in urine, MEGSIN can be detected with high frequency, accompanied by proliferation and activation of mesangial cells. Measurement of MEGSIN in urine is useful as a marker for mesangial proliferative nephropathy, such as IgA nephropathy.

In addition, the present invention relates to a transgenic nonhuman vertebrate animal in which the expression level of MEGSIN gene is altered. Herein, MEGSIN gene includes cDNA, genomic DNA, or synthetic DNA encoding MEGSIN. Gene expression includes both steps of transcription and translation. Transgenic animals of the present invention are useful for investigating function and expression control of MEGSIN, clarifying mechanisms of development of diseases relating to human mesangial cells, and developing disease model animals used for screening and testing safety of pharmaceuticals.

In the present invention, MEGSIN gene can be modified so as to artificially increase or decrease its expression level compared with the original gene by introducing mutation such as deletion, substitution, insertion, etc. in a part of some important sites (enhancer, promoter, intron, etc.) which control the normal expression of MEGSIN gene. Such modification alters transcription of MEGSIN gene. On the other hand, translation to proteins can be modified by deleting a part of an exon, or replacing a certain codon with a stop codon by introducing point mutation into coding regions. Such mutation can be introduced by the known methods for obtaining transgenic animals.

Transgenic animals means, in a narrow sense, animals into reproductive cells of which an exogenous gene is artificially introduced by genetic recombination, and in a broad sense, animals into chromosome of which an exogenous gene is stably introduced during an early developmental stage, said gene can be transmitted

to the offspring as genotype, including antisense transgenic animals in which the function of a specific gene is inhibited by antisense RNA, animals in which a specific gene is knocked out by using embryonic stem cells (ES cells), and animals into which point mutation DNA is introduced. Transgenic animals used  
5 herein include all vertebrates except for human.

Transgenic animals can be prepared by the method comprising mixing a gene with an egg and treating the mixture with calcium phosphate, the microinjection method whereby a gene is directly  
10 injected into a nucleus in pronuclear egg by a micropipette under the phase contrast microscope (microinjection method, U.S. Patent No. 4,873,191), and the method using embryo stem cells (ES cells). Other methods include, for example, the method in which a gene is inserted into a retrovirus vector to infect an  
15 egg and the sperm vector method in which a gene is introduced into an egg through sperm, etc. The sperm vector method is a genetic recombination method for introducing an exogenous gene by attaching an exogenous gene into sperm or incorporating an exogenous gene into sperm cells by electroporation, etc. and  
20 fertilizing an egg (M. Lavitrano et al., Cell, 57, 717, 1989).

*In vivo* Site specific genetic recombination such as cre/loxP recombinase system of bacteriophage P1, FLP recombinase system of *Saccharomyces cerevisiae*, etc. can be used. The method for introducing a transgene of a target protein into nonhuman  
25 animals using retrovirus has been reported.

Transgenic animals can be prepared by microinjection, for example, in the following manner. A transgene basically composed of a promoter regulating expression, a gene encoding a specific protein, and polyA signal is provided. Expression pattern and  
30 level for all lineages should be confirmed since the expression pattern and level of a specific molecule depend on the promoter activity, and prepared transgenic animals vary among lineages depending on the number of copies and introduction site on chromosomes of an introduced transgene. A sequence of introns  
35 to be spliced at upstream of polyA signal may be introduced when the expression level is known to vary depending on noncoding

region and splicing. It is important to use a gene as pure as possible for introducing into a fertilized egg. An animal to be used includes a mouse for collecting fertilized eggs (5 to 6 weeks old), male mouse for crossing, pseudopregnant female mouse, vasoligated male mouse, etc.

To efficiently obtain fertilized eggs, ovulation can be induced by gonadotropin, etc. A fertilized egg is collected, and a gene is injected into a male pronucleus of the egg by microinjection using an injection pipette. Animals for returning the treated eggs into an oviduct are prepared (pseudopregnant female mice, etc.), and about 10 to 15 eggs are transplanted per each individual. Introduction of the transgene into a new-born mouse is confirmed by extracting genomic DNA from the tip of the tail and detecting the transgene by Southern hybridization or PCR methods, or by the positive cloning method in which a marker gene that is activated only upon homologous recombination is inserted. Expression of the transgene can be confirmed by detecting a transgene-derived transcript by Northern hybridization or RT-PCR methods. Detection by Western blotting method is also possible using a antibody specific to a protein.

A knockout mouse of the present invention is prepared so as to lose the function of MEGSIN gene. A knockout mouse means a transgenic mouse in which a certain gene is destroyed by homologous recombination technology to eliminate its function. A knockout mouse can be prepared by conducting homologous recombination using ES cells and selecting ES cells in which one allele is modified and destroyed. For example, genetically manipulated ES cells are injected into a blastocyst or an 8-cell embryo of an fertilized egg to obtain a chimeric mouse having both cells derived from ES cells and from embryo. A heterozygous mouse in which all of one allele is modified and destroyed can be prepared by crossing a chimeric mouse (chimera means an individual composed of somatic cells derived from two or more fertilized eggs) and a normal mouse. Crossing of heterozygous mice with each other can produce homozygous mice. A transgenic

animal of the present invention includes both heterozygotes and homozygotes.

Homologous recombination means the recombination occurring between two genes whose nucleotide sequences are the same or extremely similar through mechanism of genetic recombination. Cells with homologous recombination can be selected by PCR. Homologous recombination can be confirmed by performing PCR using as primers sequences of a part of a gene to be inserted and a part of a chromosomal region into which the gene is expectedly inserted and detecting cells producing amplified products. Homologous recombination in the genes expressed in ES cells can be easily screened by known methods or their modified methods, for example, by binding neomycin resistant gene to the introduced gene to make the cells neomycin resistant after the introduction.

#### Brief Description of the Drawings

Figure 1 shows the amino acid sequence of MEGSIN. The underlined part shows "SERPIN" signature. The boxed part and the arrow show reactive site loop (RSL) and putative reaction site, respectively. The two putative hydrophobic regions are indicated by the dotted lines.

Figure 2 shows the comparison of amino acid sequences of MEGSIN with other proteins belonging to SERPIN super family. In panel (A), homologous regions are indicated by the bars. Gaps between the bars show spaces inserted in database sequences for the optimization of alignment, and the lines across the bars show the regions where residues are inserted into database sequences compared with the subject sequence. These sequences are aligned by following the protein scoring matrix pam 250. The scores are shown at the right of the bars (a maximum potential score is 1820). Panel (B) shows the comparison of RSL of SERPIN. P17-P5' of RSL is aligned (based on numbering by Schecher and Berger). Nonpolar residues are shown by the bold letters. "SCC1," "ILEU," "PAI-2," and "ova" represent squamous epithelial cell carcinoma antigen 1 (SCCA1), elastase inhibitor, plasminogen activator

inhibitor-2 (PAI-2), and ovalbumin respectively.

Figure 3 shows the detected MEGSIN transcript by Northern blot analysis. Lane 1 represents mesangial cells, lane 2 promyelocytic leukemia HL-60, lane 3 Hela cells S3, lane 4 chronic myeloid leukemia K-562, lane 5 lymphoblastic leukemia MOLT-4, lane 6 Burkitt's lymphoma Raji, lane 7 adenocarcinoma of the large intestine SW480, lane 8 lung cancer A549, and lane 9 melanoma G361. The experiment was conducted as follows. Human Multiple Northern Blot containing 2  $\mu$ g each of poly (A)<sup>+</sup>RNA derived from heart, brain, placenta, lung, liver, skeletal muscle, kidney, and spleen (Clontech, CA, USA) and Human Cancer Cell Lineage Northern Blot containing 2  $\mu$ g each of poly (A)<sup>+</sup>RNA derived from promyelocytic leukemia HL-60, Hela cell S3, chronic myeloid leukemia K-562, lymphoblastic leukemia MOLT-4, Burkitt's lymphoma Raji, adenocarcinoma of the large intestine SW480, lung cancer A549, and melanoma G361 (Clontech, CA, USA) were used. RNA was isolated from human mesangial cultured cells, and poly (A)<sup>+</sup> RNA (2  $\mu$ g) was separated by 1% agarose gel containing 2.2 M formamide, and transferred onto the blotting filter described above. The filter was hybridized in "Rapid Hyb solution (Amersham)" and washed at 60°C to achieve final stringency of 0.1 X SSPE/0.1% SDS.

Figure 4 is a photograph showing the result of RT-PCR. Lane 1 represents mesangial cell, lane 2 smooth muscle cell, lane 3 fibroblast, lane 4 endothelial cell, lane 5 renal epithelial cell, lane 6 keratinocyte, lane 7 monocyte, and lane 8 polymorphonuclear leukocyte (the upper photograph). The total RNA was isolated from human cultured cells, and reverse transcription was conducted using "T-Primed-First-Strand" kit (Pharmacia Biotech). Amplification by PCR was carried out with 25 cycles using DNA Thermal Cycler (Perkin Elmer). Each cycle was composed of denaturation at 94°C for 1 min, annealing at 60°C for 2 min, and extension at 72°C for 2 min using oligonucleotide primers of MEGSIN: sense 5'-ATGATCTCAGCATTGTGAATG-3' and antisense 5'-ACTGAGGGAGTTGCTTTTCTAC-3'. The estimated size of amplified fragment was 773 bp. In order to compare RNA level among different



samples,  $\beta$  actin was used as the RNA internal control (the lower photograph). The PCR product was separated by electrophoresis on 1% agarose gel.

Figure 5 is a photograph showing the result of *in situ* hybridization, indicating the expression of MEGSIN in mesangial cells in glomeruli from the normal subjects and IgA nephropathy patients. Panel (A) shows two glomeruli of IgA-N patients (40x magnification). MEGSIN signal was not observed in the uriniferous tubule or mesangial region. Panel (B) is the same photograph of 80x magnification. MEGSIN signal was observed in mesangial region of IgA-N patients. Panel (C) is the same photograph of 200x magnification, showing that mesangial cells are MEGSIN positive but endothelial cells and Bowman's capsule cells are MEGSIN negative.

Figure 6 shows the result of Western blotting using the polyclonal antibody specific to MEGSIN of the present invention. Lane 1 represents MBP, lane 2 MBP-MEGSIN fusion protein, lane 3 MBP-PAI II fusion protein, lane 4 PAI-I, and lane 5 albumin.

Figure 7 is a graph showing MEGSIN measured by ELISA in the urine samples. The ordinate shows absorbance at 492 nm, and the abscissa shows the dilution ratio of the urine samples. MEGSIN was not detected in the normal subjects(-O-, -Δ-, and -◇-), but detected in the urine from IgA nephropathy patients (-■-, -◆- and -▲-) and MBP-MEGSIN(-●-).

#### Best Mode for Implementing the Invention

The present invention is illustrated in detail below with references to examples, but is not to be construed as being limited thereto.

#### Example 1: Primary culture of human mesangial cells

Human glomerular renal mesangial cells were isolated from the normal human kidney excised from a 58 year-old male. Renal cortex was separated under the sterilized condition, minced, and passed through several sieves. Pore diameters of the used sieves were decreased stepwise, and the trapped glomerulus by the sieve

at the pore diameter of 75 to 200 nm was washed and incubated with 100  $\mu$ g/ml collagenase (Washington Biochemical) at 37°C for 20 min. After washing, the glomerulus was resuspended in medium 199 (Gibco BRL, Gaithersburg, MD) containing 25 mM Hepes, 10% Nu-serum (Collaborative Biomedical Products, Bedford, MA), and antibiotics (100 mg/ml of penicillin, streptomycin, and Fungizone), and incubated in the 5% CO<sub>2</sub> incubator. At the third passage, mesangial cells were identified based on a series of criteria such as typical morphological characteristics, resistance to trypsin, puromycin, and D-valine, positiveness against immunostaining of actin (Zymed Laboratories, San Francisco, CA), anti-very late antigen (VLA)-1, 3, 5 (Immunotech), and negativeness against immunostaining of VIII factor (Dako, CA).

Example 2: Isolation of mRNA from human cultured mesangial cells

At the sixth passage, total RNA was isolated from human mesangial cells using guanidine isothiocyanate (GTC) method. The confluent culture of the mesangial cells in the medium containing serum of the cells of Example 1 was washed with phosphate buffer saline (PBS), and dissolved in 5.5 mM GTC solution. DNA was removed by passing through an 18-gauge needle. Nuclei and other cell debris were precipitated by centrifugation at 5,000 x g for 90 sec. Supernatant was carefully loaded on the layer of cesium trifluoroacetate (CsTFA) and centrifuged at 125,000 x g at 15°C for 24 hours. RNA pellet was dissolved in TE buffer. Poly (A)<sup>+</sup> RNA was isolated using oligo dT cellulose column (Pharmacia).

Example 3: Construction of 3'-directed cDNA library

cDNA was synthesized using the vector primer based on pUC19 (Norrand J. et al., Gene, 26, 101-106, 1983) with poly (A)<sup>+</sup> RNA as a template. This vector primer DNA comprised the *HincII* end and the *PstI* end with a T tale, and dam-methylated at the *MboI* site (GATC). After synthesizing the second strand, the cDNA sequence and the single *BamHI* site in LacZ gene of the vector

00508997-052700  
were digested with *MboI* and *BamHI*, respectively, and circularization and ligation were conducted at the low DNA concentration. A portion of the ligation mixture was transformed to *E. coli*. The obtained transformants were randomly selected and individually dissolved by simply heating. The inserted sequence of cDNA was amplified by the paired PCR using primers (5'-TGTAACGACGGCCAGT-3'/SEQ ID NO: 7 and 5'-ACCATGATTACGCCAAGCTTG-3'/SEQ ID NO: 8) flanking the pUC19 cloning site. The obtained short double stranded DNA was used for the cycle sequence determination reaction and analyzed by an automatic sequencer.

#### Example 4: Isolation of genes expressed specifically in mesangial cells

15 In order to identify genes expressed specifically in mesangial cells, the present inventors conducted large scale DNA sequencing and data processing by computers. Transcripts in the various different cells and organs could be simultaneously compared (Y. Yasuda et al., submitted; K. Matsubara et al., Gene. 20 135, 265, 1993; K. Okubo et al., Nat. Gen. 2, 173, 1992). Large scale DNA sequencing of the 3'-directed cDNA library of human cultured mesangial cells was conducted, and randomly selected 1836 clones were sequenced for their partial sequences. The sequence homology among clones was mutually compared, and further 25 compared with that in DNA data bank GenBank using FASTA program. mRNA from various organs and cells were analyzed using dot blot to select clones expressed specifically in mesangial cells. Among clones detected exclusively in the mesangial cell cDNA library, the major clone was obtained. This clone contained 0.3% 30 of total mRNA.

#### Example 5: Cloning of full length strand by 5' Race method

The following experiment was carried out using "5'-Full RACE Core Set" (Takara). To a 0.5ml microtube were added 4.0 35  $\mu$ l of poly (A)<sup>+</sup> RNA (0.5  $\mu$ g/ $\mu$ l) prepared from human cultured mesangial cells, 1.5  $\mu$ l of 10x RT buffer, 0.5  $\mu$ l of RNase inhibitor

(40 U/ $\mu$ l), 1  $\mu$ l of AMV Reverse Transcriptase XL (5U/ $\mu$ l), 1  $\mu$ l of 5' end phosphorylated RT primer (5'- pTCAGAGAGGTCATTC/SEQ ID NO: 9, 200 pmol/ $\mu$ l). The mixture was made up to 15  $\mu$ l with 7  $\mu$ l of RNase Free dH<sub>2</sub>O. This reaction mixture was set in "Takara PCR Thermal Cycler" (Takara) and incubated at 30°C for 10 min, at 50°C for 60 min, 80°C for 2 min, and at 40°C for 10 min to obtain the first strand cDNA.

A 15  $\mu$ l aliquot of the reaction mixture was added to a 0.5- $\mu$ l microtube containing 15  $\mu$ l of 5 X hybrid RNA denaturation buffer and 45  $\mu$ l of H<sub>2</sub>O. RNaseH (1  $\mu$ l) was added thereto, and reacted at 30°C for 1 hour. After the completion of the reaction, 150  $\mu$ l of ethanol was added thereto, cooled at -70°C for 30 min, and centrifuged to remove supernatant and collect precipitate.

To the obtained precipitate were added 8  $\mu$ l of 5 X RNA (ssDNA) ligation buffer, 20  $\mu$ l of 40% PEG #600, and 12  $\mu$ l of H<sub>2</sub>O . It was mixed well. T4 ligase (1  $\mu$ l) was added thereto, and reacted at 16°C for 15 hours to obtain the circularized single strand cDNA.

The obtained circularized single strand cDNA was diluted 10 fold with TE buffer and used as a template for the first PCR. The reaction mixture contained 5  $\mu$ l of 10 X LA PCR buffer II (Mg<sup>2+</sup> plus), 8  $\mu$ l of dNTP mixture (2.5mM), 0.5  $\mu$ l of first PCR S1 primer (5'-TCATTGATGGGTCCTCAA /SEQ ID NO: 10, 20 pmol/ $\mu$ l), 0.5  $\mu$ l of first PCR A1 primer (5'-AGATTCTTGAGCTCAGAT /SEQ ID NO: 11, 20 pmol/ $\mu$ l), and 0.5  $\mu$ l of TaKaRa LA Taq TM (5U/ $\mu$ l), which was made up to 50  $\mu$ l with sterilized water. It was set in "Takara PCR Thermal Cycler" and reacted under the condition with 25 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 2 min after heated at 94°C for 3 min.

The reaction mixture containing 1  $\mu$ l of the first PCR product as a template, 5  $\mu$ l of 10 X LA PCR TM buffer II (Mg<sup>2+</sup> plus), 8  $\mu$ l of dNTP mixture (2.5 mM), 0.5  $\mu$ l of the second PCR S2 primer (5'-AATGGTGGCATAAACATG /SEQ ID NO: 12, 20 pmol/ $\mu$ l), 0.5  $\mu$ l of the second PCR A2 primer (5'-ACAGACAAATTGAACTTC /SEQ ID NO: 13, 20 pmol/ $\mu$ l), and 0.5  $\mu$ l of TaKaRa LA Taq TM (5U/ $\mu$ l), which was made up to 50  $\mu$ l with sterilized water, was set in "Takara PCR

Thermal Cycler." The reaction was conducted under the condition with 30 cycles of 94°C for 30 sec, 60°C for 30 sec, and 72°C for 2 min.

The obtained bands were confirmed by the 0.75% agarose gel electrophoresis and 1  $\mu$ l from the product was subcloned using "Original TA Cloning Kit" (Invitrogen). The obtained plasmid was named as "pCR-942-5.3." The nucleotide sequence of the inserted gene fragment was sequenced by the dideoxy termination method.

The obtained nucleotide sequence contained about 600 nucleotides encoding the N-end of the gene product and about 400 nucleotides as the 5' noncoding region. The putative initiation codon ATG was coincident with the consensus sequence that provides the longest open reading frame (satisfying "the first ATG rule"). The nucleotide sequence of MEGSIN cDNA and the deduced amino acid sequence of MEGSIN were shown in SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

#### Example 6: Expression of protein

In order to obtain a gene comprising coding regions, PCR reaction was conducted with 1.0  $\mu$ l of poly (A)<sup>+</sup>RNA (0.5  $\mu$ g/ $\mu$ l) from human cultured mesangial cells as a template, and the primers designed so as to encode the coding regions, that is, the primer comprising the initiation codon with the restriction enzyme *EcoRI* recognition sequence at the 5' end (5'-GAATTCATGGCCTCCCTTGCTGCAGCAAA/SEQ ID NO: 14), and the primer with the stop codon and the *SalI* recognition sequence (5'-GTCGACTTATCAAGGGCAAGAACTTTGCC/SEQ ID NO: 15). The reaction mixture contained 5  $\mu$ l of 10 X Ex Taq buffer, 8  $\mu$ l of dNTP mixture (2.5 mM), 0.5  $\mu$ l of the PCR primer (5'-GTCGACTTATCAAGGGCAAGAACTTTGCC, 20 pmol/ $\mu$ l), 0.5  $\mu$ l of the first PCR A1 primer (5'-GAATTCATGGCCTCCCTTGCTGCAGCAAA, 20 pmol/ $\mu$ l), and 0.5  $\mu$ l of TaKaRa Ex Taq TM (10U/ $\mu$ l), which was made up to 50  $\mu$ l with sterilized water, and set in "Takara PCR Thermal Cycler" to react under the condition with 30 cycles of 94°C for 1 min, 60°C for 2 min, and 72°C for 2 min. The amplification was

confirmed by 0.75% agarose gel electrophoresis, and 1  $\mu$ l of the reactant was subcloned using "Original TA Cloning Kit" (Invitrogen). The obtained plasmid was named as pCR-942CD-11/2. *E. coli* JM 109 transformed with pCR-942CD-11/2 has been deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (Accession No. FERM BP-6518). This plasmid was digested with *EcoRI* and *SalI*. The inserted gene was ligated with *EcoRI*- and *SalI*-digested pMAL-c (New England Biolab), an expression vector for maltose binding protein-fusion protein, through T4 ligase, and *E. coli* XL1-Blue was transformed with this product. After 18 hours, the ampicillin resistant cells were added to 3 ml of LB medium and cultured for 18 hours. The plasmid was extracted by the miniprep method, and confirmed by the restriction enzymes to obtain expression vector pMAL-MEGSIN. *E. coli* XL1-Blue transformed with pMAL-MEGSIN has been internationally deposited at National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (Accession No. FERM BP-6517).

International deposit of *E. coli* JM 109 transformed with pCR-942CD-11/2:

(a) Address and Name of depositary institution

Name: National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry

Address: 1-3, Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan (zip code: 305-0046)

(b) Date of deposition (Original date of deposition)

September 22, 1997

(c) Accession No. FERM BP-6518

International deposit of *E. coli* XL1-Blue transformed with pMAL-MEGSIN:

(a) Address and name of depositary institution

Name: National Institute of Bioscience and Human-

Technology, Agency of Industrial Science and  
Technology, Ministry of International Trade  
and Industry

Address: 1-3, Higashi 1-Chome, Tsukuba-shi, Ibaraki-  
ken, Japan (zip code: 305-0046)

(b) Date of deposition (Original date of deposit)

September 22, 1997

(c) Accession No. FERM BP-6517

*E. coli* XL-Blue transformed with pMAL-MEGSIN was added to  
10 ml of LB medium containing 100  $\mu$ g/ml ampicillin, and cultured  
at 37°C for 18 hours with shaking. This cultured medium was added  
to 1 liter of Rich medium (containing 10 g of tryptone, 5 g of  
yeast extract, 5 g of NaCl, 2 g of glucose, and 100  $\mu$ g/ml  
ampicillin) and cultured at 37°C with shaking. When the culture  
medium reached about 0.4 OD (A600) measured by a turbidimeter,  
3 ml of 0.1 M IPTG (1.41 g of isopropyl- $\beta$ -D-thiogalactoside  
diluted with 50 ml of water) was added thereto, and further  
cultured at 37°C with shaking. After 2 hours, the cells were  
collected by centrifugation (4000 X g, 20 min), and 50 ml of lysis  
buffer (10 mM Na<sub>2</sub>HPO<sub>4</sub>, 30 mM NaCl, 0.25% Tween20, pH 7.0) was added.  
The cells were well suspended, frozen at -80°C for 18 hours, and  
sonicated (SONIFIER 250: BRANSON) to destroy cells. NaCl was  
added thereto to 0.5 M and centrifuged (10000 X g, 30 min) to  
collect supernatant. , of 0.25% Tween 20/column buffer was added  
to the supernatant, and the mixture was loaded onto the column  
filled with 30 ml of amylose resin equilibrated with 0.25% Tween  
20/column buffer (0.25% Tween 20, 10 mM phosphoric acid, 0.5 M  
NaCl, pH7.2). The column was washed with 100 ml of 0.25 % Tween  
20/column buffer at 1ml/min flow rate, and then with 150 ml of  
column buffer. The fusion protein binding to the amylose resin  
was eluted with 50 ml of column buffer containing 10 mM maltose.  
This was concentrated to about 1 mg/ml by a ultrafiltration device  
(Amicon stirred-cell concentrator).

The fused maltose binding protein can be digested and  
removed by the enzymes through the following method. The protein  
solution is added to a dialysis tube (molecular weight cutoff:

5

10

15

20

35



characteristic of SERPIN existed at the COOH end. Four putative N-glycosylated sites existed. Obvious NH<sub>2</sub> end signal peptide sequence was not detected, but two hydrophobic regions existed in  $\alpha$ helix A (amino acids 1 to 16) and  $\alpha$ helix B (amino acids 27 to 44). These are thought to play an important role in transfer of SERPIN (G. von Heijne et al., J. Biol. Chem. 266, 15240, 1991; D. Belin, Thromb. Haemost. 70, 144, 1993; and D. Belin et al., EMBO J. 15, 468, 1996). Some of SERPIN family proteins may be secreted by a non-degradable internal signal sequence in  $\alpha$ helix A and  $\alpha$ helix B, or exists as a dualistic molecule existing in cytoplasm (R. D. Ye et al., J. Biol. Chem. 263, 4869, 1988; A. Wohlwend et al., J. Immunol. 139, 1278, 1987; A. Wohlwend et al., J. Exp. Med. 165, 320, 1987; C. Genton et al., J. Cell Biol. 104, 705, 1987; and P. Mlkus et al., Eur. J. Biochem. 218, 1071, 1993). Comparison with other proteins of SERPIN super family indicated that amino acids 334 to 352 corresponded to the reactive site loop (RSL) (P16-p5') (P. C. Hopkins et al., Science 265, 1893, 1994; K. Aertgeerts et al., Nature Struct. Biol. 2, 891, 1995; P. A. Patston et al., FEBS Let. 383, 87, 1996; and H. T. Wright, BioEssays. 18, 453, 1996) (Figure 2). Although some of SERPIN do not inhibit protease, transport hormones, or control blood pressure. There are three evidences showing that MEGSIN is a protease inhibitor. First, Peven residue of RSL in MEGSIN is not electrically charged, small, and nonpolar. These are characteristics of SERPIN protease inhibitors. Second, SERPIN protease inhibitors comprise the sequence of "Ala-Ala (Thr)-Ala-Ala" at the NH<sub>2</sub> end region of RSL (P12-P9), called hinge region. P12-P9 of RSL in MEGSIN is "ATAA." The P17-P8 sequence of RSL in MEGSIN (EGTEATAAT) is actually coincident with the consensus sequence (EGTEAAAAT) of SERPIN protease inhibitors. Third,  $\beta$  sheet region exists just before the NH<sub>2</sub> end region of RSL. This is essential for protease inhibition and limits the size and electrical charge of amino acids in the hinge region for achieving appropriate change of conformation. MEGSIN conserves this  $\beta$  sheet region.

Residues flanking the bond which is deduced to be easily

cleaved in RSL (P1 and P'1) are Lys-Gln, and are supposed to be important for determining substrate specificity (T. E. Creighton et al., J. Mol. Biol. 194, 11, 1987; P. Gettins et al., BioEssays. 15, 461, 1993; P. E. Stein et al., Struct. Biol. 2, 96, 1995).

5 Any other SERPIN protease inhibitors having the sequence relating to this site are not known. SERPIN, such as Kunitz type bovine basic protease inhibitor, comprises Lys at P1 and strongly inhibits trypsin. The target serine protease of MEGSIN is, therefore, presumably lysine cleaving protease.

10

Example 8: Function analysis of MEGSIN (2) - Distribution in tissues

MEGSIN was analyzed by Northern blot as follows. RNA was isolated from human mesangial cultured cells. Poly (A)<sup>+</sup> RNA (5  
15  $\mu$ g) from the cultured cells was separated by 1% agarose gel containing 2.2 M formamide, and transferred onto a nitrocellulose filter. The filter was hybridized in Rapid Hyb solution (Amersham, Arlington Heights, IL). The blot was washed at 60 °C with final stringency of 0.1X SSPE/0.1% SDS.

20 Northern blots of multiple human tissues and of human cancer cell lines were purchased from Clontech (Palo Alto, CA). Northern blot of multiple human tissues includes each 2  $\mu$ g of poly (A)<sup>+</sup> RNA from heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. Northern blot of human cancer cell lines  
25 includes each 2  $\mu$ g of poly (A)<sup>+</sup> RNA derived from promyelocytic leukemia HL-60, Hela cell S3, chronic myeloid leukemia K-562, lymphoblastic leukemia MOLT-4, Burkitt's lymphoma Raji, adenocarcinoma of the large intestine SW480, lung cancer A549, and melanoma G361. Hybridization and washing were conducted in  
30 the same manner as described above.

Single transcript was detected in mesangial cultured cells by Northern blot analysis using MEGSIN cDNA probe, but was not detected in other organs or cell lines (Figure 3). MEGSIN transcript was not detected in poly (A)<sup>+</sup> RNA derived from human  
35 kidney. This may be because kidney comprises endothelial cells, epithelial cells, and various other cells, and less mesangial

cells.

Actually, MEGSIN transcript was amplified from renal tissues by RT-PCR. RT-PCR was conducted using total RNA isolated from human cultured cells as a template, with "T-primed-First-Strand Kit" (Pharmacia Biotech). PCR amplification was performed under the condition with 25 cycles of 94°C for 1 min, 60°C for 2 min, and 72°C for 2 min using "DNA Thermal Cycler" (Perkin Elmer Cetus). "5'-ATGATCTCAGCATTGTGAATG-3'/SEQ ID NO: 16" and "5'-ACTGAGGGAGTTGCTTTTCTAC-3'/SEQ ID NO: 17" were used as a sense primer and an antisense primer, respectively. The estimated size of the amplified fragment was 773 bp. In order to compare RNA level among different samples,  $\beta$ -actin was used as an internal RNA control. The PCR products were separated by 1% agarose gel electrophoresis. MEGSIN transcript was not amplified from human fibroblasts, smooth muscle cells, endothelial cells, epithelial cells, or keratinocyte, by RT-PCR (Figure 4).

It is known that cultured mesangial cells acquire new phenotypes when activated and/or proliferate (R. J. Johnson et al., J. Am. Soc. Nephrol. 2 (10 Suppl.), S190, 1992; and J. Floege et al., Kidney Int. 45, 360, 1994). Therefore, MEGSIN expression may be enhanced to the detectable level by Northern blot analysis only when mesangial cells are activated and/or proliferate. The result of *in situ* hybridization for human renal tissues (described below) met this hypothesis.

Example 9: Function analysis of MEGSIN (3) - Comparison of expression level between IgA nephropathy patients and normal people

Expression of MEGSIN mRNA was examined in human renal tissues obtained from 18 IgA nephropathy (IgA-N) patients and 3 normal subjects by *in situ* hybridization. *In situ* hybridization was conducted in the same manner as described above (Kidney Int. 52, 111, 1997). The nucleotide sequence of the nucleotide residues 391st to 428th of human MEGSIN cDNA was used as a probe. IgA-N patients were divided into 2 groups: patients

whose mesangial proliferation was active, but glomerulosclerosis was weak (proliferative phase, n=9), and the others whose 30% or more of glomerulus was sclerosed (sclerotic phase, n=9). MEGSIN mRNA was detected exclusively in glomeruli both in normal subjects and IgA-N patients (Figure 5A). MEGSIN transcript was localized in mesangial cells in the glomeruli (Figure 5B and Figure 5C). The pretreatment with RNase prior to hybridization for evaluating signal specificity resulted in the removal of most signals detected by the MEGSIN probe. The competitive experiment using 100 times excessive homologous or unrelating unlabeled oligonucleotides showed that MEGSIN signal disappeared by homologous oligonucleotide competitors, but not by non-homologous oligonucleotides. To quantify expression of MEGSIN mRNA, all nuclei in at least 10 glomeruli selected randomly and the nuclei comprising positive cytoplasm around them (cross section of vessel pole) were counted as blind test to calculate a percentage of the positive cells of whole nuclei. Mann-Whitney U test was used for statistical comparison. The number of MEGSIN positive cells in IgA-N during proliferative phase was significantly higher than that in kidneys of the normal subjects. These findings confirmed the hypothesis proposed by the present inventors that the expression of MEGSIN is enhanced by the activation and/or proliferation of mesangial cells.

#### Example 10: Production of anti-MEGSIN antibody

##### (1) Production of polyclonal antibody against synthetic peptide of MEGSIN

Polyclonal antibodies against MEGSIN were produced using the region comprising low homology with other members of SERPIN family and hydrophilicity. Peptide "H<sub>2</sub>N-C-S-N-I-V-E-K-Q-L-P-Q-S-T-L-F-R-COOH/SEQ ID NO: 18" comprising cysteine at the N end of 342nd to 356th peptides from the N end of MEGSIN protein was synthesized by solid phase peptide method, purified by high performance liquid chromatography, and bound to keyhole limpet hemocyanine (KLH) using m-maleimidobenzoyl-N-hydroxysuccinimidoester (MBS). A rabbit was intracutaneously

immunized with KLH binding peptide mixed with Freund's complete adjuvant (200  $\mu$ g/individual). The rabbit was additionally immunized with KLH binding peptide mixed with Freund's incomplete adjuvant (200  $\mu$ g peptide/individual) as a booster 2, 4, and 6 weeks after priming. To evaluate reactivity of sera from the blood collected after 44, 59, and 64 days with a synthetic peptide, enzyme-linked immunosorbent assay (ELISA) was conducted. The synthetic peptide was coated on a 96-well microplate (1  $\mu$ g/well), washed, and blocked with bovine serum albumin. Reactivity of the antibodies in samples of sera with various dilution ratios was determined using HRP-conjugated goat anti-rabbit IgG as a secondary antibody and O-phenylenediamine as a substrate. Absorbance was measured at 492 nm after termination of the reaction. Antibody titer was increased by 6,800, 20,500, and 25,400 times after 44, 59, and 64 days. The obtained antibody was reacted with the MEGSIN fusion protein by Western blot, demonstrating specificity to MEGSIN protein. Figure 6 shows the result of Western blot (anti peptide 342-356).

(2) Production of polyclonal antibodies against synthetic peptide of MEGSIN

Polyclonal antibodies against MEGSIN was produced using the resin comprising low homology with other members of SERPIN family and hydrophilicity in the same manner as in (1). Peptide

(1) "H<sub>2</sub>N-C-F-R-E-M-D-D-N-Q-G-N-G-N-V-F-F-COOH/SEQ ID NO: 19" comprising cysteine at the N end of peptide 16th to 30th from the N end of MEGSIN protein, Peptide (2) "H<sub>2</sub>N-C-S-Q-S-G-L-Q-S-Q-L-K-R-V-F-S-D-COOH /SEQ ID NO: 20" comprising cysteine at the N end of peptide 72nd to 86th, and Peptide (3) "H<sub>2</sub>N-A-T-G-S-N-I-V-E-K-Q-L-P-Q-S-T-L-C-COOH /SEQ ID NO: 21" comprising cysteine at the C end of peptide 339th to 354th from the N end were synthesized by solid phase peptide method. These peptides were bound to bovine thyroglobulin (Sigma) using N-(6-maleimidocaproyloxy) succinimide (EMCS, Dojin Kagaku Kenkyu-syo (Dojindo)), dialyzed against 0.85% NaCl, and mixed well with adjuvant for emulsification, and subcutaneously administered to

a rabbit. Three weeks after priming (20  $\mu$ g/individual), the second immunization (50  $\mu$ g/individual) was performed, and further four immunizations (50, 50, 100, 200  $\mu$ g/individual) were conducted every other week. Freund's complete adjuvant (Difco) was used only for priming, and Freund's incomplete adjuvant (Difco) was used for the rest. Antibody titer in the serum obtained by the blood collection was evaluated by ELISA after 41 and 55 days.

The serially diluted antiserum (100  $\mu$ l) was added to each well of the 96 well microplate coated with 50 ng/well of antigen for the first reaction, washed, and reacted with HRP conjugated goat anti-rabbit IgG (Meneki-kagaku Kenkyu-syo (Immunochemistry Institute)) as the second reaction. After washing, orthophenylenediamine (Wako Pure Chemical Industries) was used as a substrate for coloring, and absorbance was measured at 492 nm (SPECTRAMax 250, Molecular Devices).

As a result, antibody titer was increased by 6,400 and 51,200 times for peptide (A) and peptide (B), respectively 55 days after the additional immunization. Antibody titer of peptide (C) was increased 102,400 and 204,800 times 41 and 55 days after the additional immunization, respectively. Each of the obtained antibodies was confirmed to react with MBP-MEGSIN fusion protein by Western blot, demonstrating specificity to MEGSIN protein. Figure 6 shows the result (peptide 2: 72-86, peptide 3: 339-354). The reaction specific to MBP-MEGSIN fusion protein was observed.

### (3) Production of polyclonal antibody against MBP-MEGSIN

The concentrated fusion protein MBP-MEGSIN (10 mM sodium phosphate, 0.5 M NaCl, and 10 mM maltose) obtained in Example 6 was mixed with the same volume of Freund's complete adjuvant and emulsified well. This emulsion (0.5 ml) was subcutaneously administered to a New Zealand White rabbit (female, about 4000g) (20  $\mu$ g/animal). The rabbit was additionally immunized with MBP-MEGSIN mixed with Freund's incomplete adjuvant, 3 weeks (50  $\mu$ g/animal), 5 weeks (50  $\mu$ g/animal), 7 weeks (50  $\mu$ g/animal), 9

weeks (100  $\mu$ g/animal), and 11 weeks (200  $\mu$ g/animal) after priming. One week after third immunization, the blood sample was experimentally collected to measure antibody titer, resulting in increase of 204,800 times. The measurement of antibody titer was conducted by EIA using the 96 well-plate fixed with 50 ng/well antigen. Serially diluted antiserum (100  $\mu$ g) was added to each well to conduct the first reaction, and the supernatant was removed. The plate was washed, reacted with anti-rabbit IgG Fab'-HRP (IBL, Japan), washed again, and measured by coloring with OPD (Sigma, USA). The obtained antiserum was confirmed to react specifically with MBP-MEGSIN by Western blot.

#### (4) Production of monoclonal antibody against MBP-MEGSIN

The concentrated fusion protein MBP-MEGSIN (10 mM sodium phosphate, 0.5 M NaCl, and 10 mM maltose) obtained in Example 6 was mixed with the same volume of Freund's complete adjuvant and sufficiently emulsified. This emulsion was subcutaneously and intracutaneously administered to three 7 week-old Balb/c mice with 27G injection needles. The mice were immunized using Freund's incomplete adjuvant further 4 times every 7 days (the first immunization: 20  $\mu$ g/mouse, the second to forth: 10  $\mu$ g/mouse). After four immunizations, a small amount of blood was collected from the tail vein for measuring antibody titer by EIA using the immunoplate coated with 50 ng/well antigen. Accordingly, the splenic cells of the mice were fused with myeloma cell line X-63 Ag8 by the standard method using PEG. Monoclonal antibody producing hybridoma specific to immunogen can be selected by screening using EIA with the 96-well plate coated with immunogen, MBP, BSA, etc.

#### Example 11: Production of monoclonal antibody against MEGSIN

##### (1) Production of monoclonal antibody against His-Tag-MEGSIN

##### (a) Expression of His-Tag-MEGSIN

To obtain the gene comprising the coding region, total RNA was collected from human cultured mesangial cells using ISOGEN (Nippon Gene). cDNA was synthesized using Super Script II

(GIBCO) as a reverse transcriptase. Using a part of this cDNA as a template, primers were designed so as to encode the coding region, that is, the primer EX-MEG1-2 comprising the initiation codon and the recognition sequence of restriction enzyme *Bam*HI added at the 5' end (5'-ATCGGATCCATGGCCTCCCTTGCTGCAGCAAATGCAGA-3'/SEQ ID NO: 22) and the primer EX-MEG2-2 comprising the stop codon and the *Hind*III recognition sequence (5'-ATAAGCTTTCATCAAGGGCAAGAACTTTGCCACTGAATAAG-3'/SEQ ID NO: 23). PCR reaction was conducted using these primers and LA Taq (TaKaRa).

Reaction was performed in the reaction mixture containing 2.5  $\mu$ l of 10 X LA Taq buffer, 4  $\mu$ l of dNTP mixture (2.5 mM), 2.5  $\mu$ l of 25 mM magnesium chloride, 1  $\mu$ l each of 20  $\mu$ M PCR primers EX-MEG1-2 and EX-MEG2-2, 2.5 units of LA Taq, and cDNA, which was made up to 25  $\mu$ l with sterilized water.

Each reagent was set on Gene Amp PCR System 9700 (Applied Biosystems) and reacted under the condition with 35 cycles of 96°C for 1 min, 60°C for 30 sec, and 72°C for 2 min after heating at 96°C for 3 min.

After the completion of reaction, PCR product was collected, treated with restriction enzymes *Bam*HI (Takara) and *Hind*III (Takara), and subcloned to pUC18 with Ligation Kit ver. I (Takara). This plasmid was cultured in a small scale, collected with Wizard Plus Miniprep DNA Purification System (Promega) to confirm the gene sequence, and digested with *Bam*HI and *Hind*III again to insert into multi cloning site in ptrcHisA (Invitrogen), a vector for protein expression, using Ligation Kit ver. I to obtain ptrcHisA-MEGSIN.

The prepared plasmid was transformed into *E. coli* JM 109, cultured on LB agar medium with 100  $\mu$ g/ml ampicillin to select ampicillin resistant cells, cultured in 20 ml of LB medium with 100  $\mu$ g/ml ampicillin at 37°C overnight with shaking, and further cultured in 20 L of LB medium with 100  $\mu$ g/ml ampicillin at 37°C for 3 to 4 hours with shaking. When the absorbance was about 0.5 OD (A600) (Shimadzu, BIOSPEC-1600), isopropyl-beta-D-



thiogalactoside (IPTG: Takara) was added to the final concentration of 1 mM, and cultured at 37°C for 3 hours with shaking. The cells were collected by centrifugation, and washed with PBS. The expressed protein was collected using Ni-NTA Spin Kits (QIAGEN). The detail is as follows.

The sample was suspended in 50 ml of Buffer A (6M GuHCl, 0.1 M Na-phosphate, and 0.01 M Tris-HCl, pH 8.0), stirred for 1 hour at room temperature, and centrifuged at 10000 g for 15 min at 4°C to collect the supernatant. To this supernatant, 8 ml of Ni-NTA previously equilibrated with Buffer A was added, stirred for 1 hour at room temperature, and transferred to the column. The column was washed with 80 ml of Buffer A, washed with 20 ml of Buffer B (8M Urea, 0.1 M Na-phosphate, and 0.01 M Tris-HCl, pH 8.0), and eluted with 20 ml of Buffer C (8M Urea, 0.1 M Na-phosphate, and 0.01 M Tris-HCl, pH 6.3). After the expressed protein was collected in the above manner, the eluted fraction was confirmed by SDS-PAGE. The positive fraction was separated by SDS-PAGE and stained with CBB to extract the target band. The extracted band was immersed in Protein Extraction Buffer to elute the protein.

(b) Production of monoclonal antibody against His-Tag-MEGSIN

The MEGSIN fusion protein was mixed with the same volume of Freund's complete adjuvant, and emulsified well. The emulsion was subcutaneously and intracutaneously injected to three 7-week old Balb/c mice with the 27G injection needle. The mice were further immunized 4 times using Freund's incomplete adjuvant every 7 days after priming. The amounts of antigen applied were 20 µg/mouse for the first immunization and 10 µg/mouse for the second to forth. A small amount of blood was collected from the tail vein, and antibody titer was measured after the four immunizations. Antibody titer was assayed by ELISA using the 96-well plate coated with the 50 ng/well antigen. Accordingly, the mouse splenic cell was fused with myeloma cell line X-63 Ag8 by the standard method using PEG, and screened by ELISA using the 96-well plate coated with His-Tag-MEGSIN, histidine, or BSA,

or Western blot. Monoclonal antibody producing hybridoma specific to immunogen was thus selected.

#### Example 12: Measurement of MEGSIN in urine by ELISA

5       Urine was collected from the IgA nephropathy patient and centrifuged. The obtained supernatant was concentrated using a ultrafilter for centrifugation (Millipore, Ultrafree, molecular weight cutoff: 5000). Stepwise diluted MBP-MEGSIN or concentrated urine (50  $\mu$ l) was added into each well of the 96-well  
10   plate for ELISA coated with rabbit polyclonal anti-MEGSIN antibody (IgG fraction), kept at 4°C overnight, washed with PBS (-), and blocked with Blockace (Dainippon Pharmaceutical Co., Ltd.). The plate was washed with PBS (-) containing 0.05% (w/v) Tween 20 (Tween-PBS). The biotin-labeled rabbit polyclonal  
15   anti-MEGSIN antibody was added to the plate, and kept at room temperature for 1 hour, and washed with Tween-PBS. The peroxidase-labeled streptoavidin solution (Amersham) (100 ml/well) was added to each well and washed with Tween-PBS, and 100 ml of orthophenylenediamine coloring substrate solution  
20   (Wako Pure Chemical) was added to each well. The reaction was conducted for 10 to 30 min in the dark at room temperature, and 50 ml of 2M sulfuric acid was added to each well to stop the reaction. The absorbance (492 nm) was measured by the microplate reader (SPECTRAMax 250, Molecular Devices) to determine MEGSIN  
25   concentration in the urine from calibration curve of a standard solution. The result is shown in Figure 7. MEGSIN was detected in the urine from the IgA nephropathy patients.

#### Example 13: Cloning of rat MEGSIN cDNA

##### 30   (1) Cloning of cDNA by degenerate PCR

      Using ISOGEN (Nippon Gene) and oligotex, mRNA was extracted from the rat cultured mesangial cells of the 14<sup>th</sup> passage. This mRNA was subjected to reverse transcription reaction with reverse transcriptase Super Script II (GIBCO), and the obtained cDNA was  
35   used as a template. Based on the cDNA of human MEGSIN, the degenerate primers FY: GTGAATGCTGTGTACTTAAAGGCAANTGN/SEQ ID NO:

24 (corresponding to 172VNAVYFKGK180) and R21:  
AANAGRAANGGRTCNGC/SEQ ID NO: 25 (R is A or G, corresponding to  
357ADHPFLF363) were prepared for the PCR under the condition with  
35 cycles of 94°C for 45 sec (denaturation), 50°C for 45 sec  
5 (annealing), and 72°C for 2 min (extension) using DNA Thermal  
Cycler (Perkin Elmer Cetus).

PCR product having the size similar to the expected size  
(576bp) was inserted into pCRII vector (Clontech) and sequenced  
by dideoxy method using a DNA automatic sequencer.

10 The primers specific to the gene were prepared from the  
clone fragment of rat MEGSIN, and degenerate PCR was conducted  
again for obtaining the 5' region of rat MEGSIN.

First, the degenerate primer RM-CtermC1:  
ATGGCNTCNGCNGCNGCNGCNAAYGC/SEQ ID NO: 26 (Y is T or C), which  
15 corresponds to N-terminus of the sequence encoding human MEGSIN,  
and the reverse primers specific to rat MEGSIN, RM-MR-A2:  
CGACCTCCAGAGGCAATTCCAGAGAGATCAGCCCTGG/SEQ ID NO: 27 and RM-  
MR-A1: GTCTTCCAAGCCTACAGATTTCAAGTGGCTCCTC/SEQ ID NO: 28, were  
prepared. PCR was conducted with RM-CtermC1 and RM-MR-A2 under  
20 the condition with 45 cycles of 94°C for 45 sec, 55°C for 45 sec,  
and 72°C for 1 min. Using the obtained PCR product as a template,  
nested PCR was conducted under the condition with 25 cycles of  
94°C for 45 sec, 55°C for 45 sec, and 72°C for 1 min, with RM-  
CtermC1 and RM-MR-A2. To enhance the amplification, PCR was  
25 further repeated using the same primers under the condition with  
25 cycles of 94°C for 30 sec, 55°C for 30 sec, and 72°C for 40 sec.

The obtained PCR product was inserted into pGEM-T-easy  
vector (Promega), and sequenced by dideoxy method using the DNA  
automatic sequencer.

## 30 (2) Cloning of cDNA by 5' RACE and 3' RACE methods

The sequence completely comprising the open reading frame  
without mutation at the sites of initiation codon and stop codon  
of MEGSIN was determined. 5'-RACE and 3'-RACE methods were  
35 conducted by Marathon cDNA amplification kit (Clontech) using  
the primers designed based on the sequences obtained above in

002290 2688560

order to confirm the whole length sequence. For 5'-RACE, two types of gene specific antisense primers, RM-PR01: GCTCAGGGCAGTGAAGATGCTCAGGGAAGA/SEQ ID NO: 29 and RM-PR02: CTGACGTGCACAGTCACCTCGAGCACCC/SEQ ID NO: 30 were used. For 3'-

5 RACE, the gene specific sense primer, RM-MR-S3: GAGGTCTCAGAAGAAGGCACTGAGGCAACTGCTGCC/SEQ ID NO: 31 was used. Finally, based on the sequences obtained in such a manner, whole cDNA nucleotide sequence of rat MEGSIN composed of 1229 bp shown in SEQ ID NO: 3 was almost completely determined.

10 To obtain clones comprising open reading frame of the rat MEGSIN, two kinds of gene specific primers, RM-5'UTR-FS2: CTCTATAGGAGACACTTGG/SEQ ID NO: 32 (sense primer) and 3'-UTR-A1: GAAACAAATCAAAGCAAAC/SEQ ID NO: 33 (antisense primer), designed from the sequences obtained above, were used. PCR was

15 conducted under the condition with 35 cycles of 94°C for 45 sec (denaturation), 50°C for 45 sec (annealing), and 72°C for 1 min 30 sec (extension). The PCR product of the expected size (about 1300 bp) was inserted into pCRII vector to isolate the clones containing the open reading frame of rat MEGSIN.

#### 20 Example 14: Cloning of mouse MEGSIN cDNA

##### (1) Cloning of cDNA by PCR

Using ISOGEN (Nippon Gene), 10 µg of total RNA was extracted from mouse cultured mesangial cells of the 9th passage. From this

25 RNA, first strand cDNA was synthesized using 20 pmol of oligo (dT) primer (Pharmacia) and 200 units of reverse transcriptase Super Script II (GIBCO) by reverse transcription reaction under the condition of 42°C for 50 min and 70°C for 15 min.

Based on the nucleotide sequences of human and rat MEGSIN,

30 degenerate primers MF-1: 5'-GAAATTGAAARCAARCTGASYTTYCAGAAT-3'/SEQ ID NO: 34 (R is A or G, S is C or G, and Y is C or T), MF-2: 5'-CTGASYTTYCAGAATCTAATGGAMTGGAC-3'/SEQ ID NO: 35 (S is C or G, Y is C or T, and M is A or C), and MR-4: 5'-GGAYTSAGGRAGTWGCTTTTCWACRATRRT-3'/SEQ ID NO: 36 (S is C or G,

35 Y is C or T, M is A or C, and W is A or T), were prepared. PCR was conducted using MF-1 and MR-4 under the condition with 30

cycles with 94°C for 1 min (denaturation), 60°C for 1 min (annealing) and 72°C for 30 sec (extension). Nested PCR was conducted using the obtained PCR product as a template and MF-2 and MR-4, under the same condition of the above to obtain the  
5 cDNA fragment of 300 bp.

(2) Extension of the 3' region by RACE method

Based on the sequences obtained above, the gene specific primers MMF3: 5'-GAGGTCTCAGAGGAGGGCACTGAAGCCACTGCTGCC-3'/SEQ  
10 ID NO: 37 and MMF4: 5'-CCAGTGCAGATCTCTCTGGAATTGCCTCTGGAGGTCGTC-3'/SEQ ID NO: 38 were prepared.

The new cDNA fragment of 127 bp was obtained by extending the 3'-region by RACE method (PCR: MMF4 and AP-1, nested PCR:  
15 MMF3 and AP-2) using 1.57 µg of poly (A)<sup>+</sup> mRNA with Marathon cDNA Amplification Kit (CLONTECH).

(3) Extension of 5'-region

Using 20 µg of total RNA and reverse transcriptase  
20 SuperScript II (GIBCO), the first strand DNA was synthesized. Using the gene specific primer MMR6: 5'-GCCTGTTACTGTATAGGAAACCAACCG-3'/SEQ ID NO: 39 and degenerate primer based on the nucleotide sequence of rat MEGSIN, DG-RMF1: 5'-ATGGCYTCCCTYGCTGCWGCRAATGCAGARTTTKGC-3'/SEQ ID NO: 40 (Y is  
25 C or T, W is A or T, R is A or G, and K is G or T), PCR was conducted to obtain the new cDNA fragment of 5'-region of 720 bp, and the total of 1147 bp of cDNA nucleotide sequence (SEQ ID NO: 5) was determined. The deduced amino acid sequence based on the obtained cDNA nucleotide sequence (SEQ ID NO: 6) was compared  
30 with that of rat (SEQ ID NO: 4). The N-terminus region in the mouse amino acid sequence was coincident with the sequence of 13th or more of rat. This finding suggested that mouse cDNA comprising the translation initiation site at further 5' end.

35 Example 15: Preparation of transgenic mouse

(1) Preparation of pUC-MEGSIN

From the human cultured mesangial cells, mRNA was extracted by AGPC method. Using this as a template, RT-PCR was conducted with the sense primer 5' Bam-MEG: 5'-ATCGGATCCATGGCCTCCCTTGCT-3'/SEQ ID NO: 41 (containing *Bam*HI restriction site) and the antisense primer 3' Hind-MEG: 5'-ATAAGCTTTTCATCATCAAGGGCAAG-3' SEQ ID NO: 42 (containing *Hind* III restriction site) to amplify the full length open reading frame of MEGSIN.

The obtained PCR product was digested with *Bam*HI and *Hind*III, and ligated with pUC 18 (Takara) digested with *Bam*HI and *Hind*III to prepare pUC18 inserted with the full length open reading frame of MEGSIN (pUC-MEGSIN). The nucleotide sequence of MEGSIN inserted to pUC18 was confirmed by the dideoxytermination method.

## (2) Construction of gene

In order to add the oligonucleotide (5'-GCC GCC) to upstream of initiation codon in human MEGSIN cDNA, PCR was conducted under the following conditions to synthesize the 211 bp DNA.

Using pUC-MEGSIN obtained in (1) as a template, PCR was conducted with a set of sense primer B44F: 5'-ATGGATCCGCCGCCATGGCCTCCCTTGCTGCAGCAAATGCAGAG-3'/SEQ ID NO: 43 (containing *Bam*HI site) and antisense primer H30-R: 5'-TATCCTGAGGCAGTGTTAACAAGCAAC -3' /SEQ ID NO: 44 (containing *Hpa*I site) using TaKaRa EX. Taq. (Takara). Salt was removed by ethanol precipitation, and the restriction site was prepared with *Bam*HI and *Hap*I to collect the 191 bp DNA fragment by the agarose gel electrophoresis.

From pUC-MEGSIN, the 3.5 kb fragment containing pUC18 using *Bam*HI and *Hap*I was obtained, and purified and collected by the agarose gel electrophoresis. By ligating this to the 191 bp DNA fragment of the above, the recombinant plasmid carrying human MEGSIN cDNA added with oligonucleotides, that is, pUC-New MEGSIN, was prepared, transformed to *E. coli* JM 109, and cloned. From pUC-New MEGSIN, the 1.2 kb fragment was collected using *Bam*HI and *Hind*III through agarose gel electrophoresis. The ends of this fragment were blunted using TaKaRa Blunting Kit (Takara).

002997-062700  
pBscAG-2 (constructed by introducing a *SalI*-*PstI* fragment obtained from pCAGGS into the *SalI* and *PstI* restriction sites of pBluescript II SK-) was digested with *EcoRI* to linearize, blunt-ended with TaKaRa Blunting Kit (Takara), and dephosphorylated by alkaline phosphatase (Takara). To this plasmid, the above described 1.2 kb fragment was ligated to prepare the recombinant plasmid, transformed to *E. coli* JM 109, and cloned. The clone in which the human MEGSIN cDNA was inserted in the same direction as chicken beta-actin promoter was selected by sequencing. This recombinant plasmid was named as pBscAG-2/MEGSIN.

From pBscAG-2/MEGSIN, the 3.4 kb DNA fragment was collected using *SalI* and *NotI* by the agarose gel electrophoresis.

### 15 (3) Preparation of transgenic mouse

To the pronucleus of fertilized egg of the mouse (B6C3F1 X C57/BL), 2p1 (2000 copies) of the DNA (3.4 kb) prepared in (2) was microinjected, and screening was performed by Southern hybridization described below.

20 Genomic DNA was prepared from the tail of the mouse using QIAGEN TISSUE KIT. Genomic DNA (2  $\mu$ g) was completely digested with *PstI*, separated by the 0.8 % agarose gel electrophoresis, and transferred to a nylon membrane. The DNA fragment of 1100 bp (extracted from pUC-MEGSIN with *PstI* and *HindIII* and collected by the agarose gel) was hybridized with the [<sup>32</sup>P]-dCTP labeled probe prepared by Random Primer DNA Labeling Kit Ver. 2 (Takara), at 68°C for 2 hours.

The membrane was washed finally with 0.2 X SSC/0.1% SDS, and autoradiographed.

30 The presence or absence of inserted DNA fragment and the number of copies were determined based on the appearance of the specific 1700 bp band. The direction of the inserted DNA fragment when multiple DNA fragments were inserted in tandem was determined by completely digesting 2  $\mu$ g of genomic DNA with *EcoRV* followed by the same manipulation.

35 The obtained transgenic mice (F0) were crossed with the

normal mice. The newborn mice were screened by the above method to obtain the transgenic mouse (F1). F2 mice were obtained By crossing transgenic mice comprising same heterozygous mutation (F1), and the transgenic mice comprising homozygous mutation were  
5 screened.

#### Industrial Applicability

The present invention provides a DNA expressed specifically in mesangial cells, a protein encoded by the DNA, and an antibody  
10 binding to the protein. These are specific to mesangial cells, and useful for, for example, identifying mesangial cells, and detecting abnormalities in mesangial cells. Moreover, this protein would be helpful for clarifying the functions of mesangial cells and in turn, for investigating causes of diseases relating  
15 to mesangial cells. This invention is expectedly applicable to the treatment and diagnosis, of diseases relating to mesangial cells.

002290 2680560  
0950897 062700



CLAIMS

1. A protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6, or a protein comprising an amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 in which one or more amino acids are replaced, deleted, added, and/or inserted, and functionally equivalent to the protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.
2. The protein of claim 1, comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6.
3. A DNA encoding the protein of claim 1.
4. The DNA of claim 3, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 5.
5. A DNA hybridizing with a DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 5 under the stringent condition, and encoding the protein of claim 1 or the protein functionally equivalent thereto.
6. A vector comprising the DNA of any one of claims 3, 4, and 5.
7. A transformed cell expressibly comprising the DNA of any one of claims 3, 4, and 5.
8. A method for producing the protein of claim 1, the method comprising culturing the transformed cell of claim 7 and collecting an expression product of the DNA of any one of claims 3, 4, and 5.
9. An antibody binding to the protein of claim 1.
10. The antibody of claim 9, which recognizes an epitope of a protein comprising an amino acid sequence selected from amino acid sequences of SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6.
11. The antibody of claim 10, wherein the antibody is a monoclonal antibody.
12. An immunoassay method for measuring the protein of claim

2 or its fragment, the method comprising immunologically binding the antibody of any one of claims 10 and 11, to the protein of claim 2 or its fragment.

13. A reagent for an immunoassay for the protein of claim 2 or its fragment, comprising the antibody of any one of claims 10 and 11.

14. A method for detecting mesangial proliferative nephropathy, the method comprising measuring the protein of claim 2 or its fragment contained in biological samples and comparing the measured amount with that obtained from normal samples.

15. A transgenic nonhuman vertebrate, wherein the expression level of the gene encoding MEGSIN is modified.

16. The transgenic nonhuman vertebrate of claim 15, wherein the nonhuman vertebrate is a mouse.

17. The transgenic nonhuman vertebrate of claim 16, which is a knockout mouse wherein expression of the gene encoding MEGSIN is inhibited.

002290 2668960

# ABSTRACT

A gene expressed specifically in mesangial cells. A DNA  
expressed specifically in mesangial cells; a protein encoded by  
5 this DNA; an antibody binding to this protein, etc. These  
substances are indigenous to mesangial cells and, therefore,  
useful in, for example, identifying mesangial cells and detecting  
abnormalities in mesangial cells. Moreover, the above protein  
would be helpful for clarification of the functions of masangial  
10 cells and, in its turn, for clarification of the causes of diseases  
relating to masangial cells. This protein is expectedly  
applicable to the treatment and diagnosis of diseases relating  
to masangial cells.

00508997 052700

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**  
(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER

SHIM-004

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MEGSIN PROTEIN

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application

Serial No. \_\_\_\_\_

on \_\_\_\_\_,

and was amended

on \_\_\_\_\_ (if applicable).

☒ was filed as PCT international application

Number PCT/JP98/04269

on September 22, 1998,

and was amended under PCT Article 19

on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:**

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Japan	9/275302	22 September 1997	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
PCT	PCT/JP98/04269	22 September 1998	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

**Combined Declaration For Patent Application and Power of Attorney (Continued)**

(Includes Reference to PCT International Applications)

 ATTORNEY'S DOCKET NUMBER  
SHIM-004

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

**PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:**

U.S. APPLICATIONS		STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

Karl Bozicevic, Reg. No. 28,807  
Bret E. Field, Reg. No. 37,620  
Dianna L. DeVore, Reg. No. 42,484  
Alan W. Cannon, Reg. No. 34,977

Carol L. Francis, Reg. No. 36,513  
Pamela J. Sherwood, Reg. No. 36,677  
Paula A. Borden, Reg. No. 42,344

7

Send Correspondence to:

Karl Bozicevic  
BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, California 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

 Direct Telephone Calls to:  
(name and telephone number)

Name: Karl Bozicevic  
Registration No. 28,807  
Telephone: (650) 327-3400

201	FULL NAME OF INVENTOR	FAMILY NAME / - <u>W</u> <u>Miyata</u>	FIRST GIVEN NAME <u>Toshio</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Kanagawa</u> <u>JPX</u>	STATE OR FOREIGN COUNTRY <u>Japan</u>	COUNTRY OF CITIZENSHIP <u>Japan</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>4-2-3-101, Higashinaruse, Isehara-shi</u>	CITY <u>Kanagawa</u>	STATE & ZIP CODE/COUNTRY <u>Japan 259-1117</u>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201

Toshio Miyata

DATE

June 1 2000

M:\FORMS\COMDEC.WP 5/96